I n 2002, two landmark studies were published demonstrating that the use of therapeutic hypothermia after cardiac arrest (HACA) decreased mortality and improved neurologic function (1, 2) . Out-ofhospital survivors resuscitated from ventricular fibrillation and ventricular tachycardia were cooled to 32°C-34°C for 12-24 hrs. Based on these studies, the International Liaison Committee on Resuscitation and the American Heart Association recommended the use of therapeutic hypothermia after cardiac arrest (3, 4) . Since these publications, additional outcome data have been published that reinforce the benefit of therapeutic hypothermia after out-of-hospital cardiac arrest (5) (6) (7) (8) (9) . Although cooling is relatively easy to implement, it is essential to address all necessary elements of this therapy. This article is intended to serve as a guide for therapeutic hypothermia protocol development and implementation.
A collaborative team approach is critical for successful development and implementation of a HACA protocol. As with the development of any protocol, it is important to identify and include key people from early in the planning stages to ensure success. Important members of the planning team include physician champions from emergency medicine, cardiology, pulmonary, medicine, neurology, and the critical care team. Nursing champions include clinical nurse specialists, educators, managers, and staff nurses from areas where the protocol will be used, as well as pharmacy, respiratory therapy, laboratory, and the medical supply departments.
Once the decision has been made to adopt therapeutic hypothermia as a standard of care, work sessions can be scheduled for the team to discuss the published research, protocol development, equipment needs, and an education plan. When developing the initial protocol, clinicians must approach each step systematically and consider possible barriers to successful implementation. If capital funding is required to purchase equipment, protocol developers should consider including this in early stages of planning. Networking with facilities that have successfully implemented therapeutic hypothermia protocols can be very helpful. Past experience highlighting success and avoiding pitfalls to implementation can be shared.
PROTOCOL DEVELOPMENT
The HACA protocol can be divided into four distinct phases: identification of eligible and ineligible patients, cooling induction, maintenance, and rewarming. A detailed description of protocol steps and elements is outlined in the following paragraphs with considerations for each phase of protocol development. Figure 1 is an example of a HACA protocol.
Identification of Eligible and Ineligible Patients
It is important to clearly identify patient inclusion and exclusion criteria for the protocol, for example, comatose/ unresponsive patients resuscitated after ventricular fibrillation and ventricular tachycardia arrest, pulseless electrical activity arrest, asystolic arrest, or inhospital arrest.
The initial HACA research studied individuals who were resuscitated after outof-hospital ventricular fibrillation and ventricular tachycardia arrest (1, 2) . The International Liaison Committee on Resuscitation (3) and American Heart Association (4) advise that patients resuscitated after pulseless electrical activity arrest, asystolic arrest, and in-hospital arrest may benefit from therapeutic hypothermia; however, HACA in patients other than those with ventricular fibrillation and ventricular tachycardia has not been studied in randomized controlled trials. The work group will need to decide whether patients other than those resuscitated from ventricular fibrillation or ventricular tachycardia arrests will be included in the protocol. Many facilities include patients resuscitated from all car-diac rhythms because from a physiologic standpoint, neurologic injury is detrimental regardless of the causative dysrhythmia. Patients resuscitated and in subsequent shock have also shown benefit from cooling therapy (10) .
Guidelines for exclusion criteria should be outlined as part of the protocol. Some protocol exclusions may require discussion on a case-by-case basis. It is helpful to outline in the protocol those patients who are considered as relative or absolute exclusions from hypothermia intervention. Some protocol exclusions may include prolonged resuscitation efforts (Ͼ60 mins), baseline comatose or impaired cognitive function, do-notresuscitate status, end-stage terminal illness, active bleeding, coagulopathy, or pregnancy.
Determining Where HACA Will Be Implemented
It is important to decide where HACA will be implemented. Is the emergency medical system in your area initiating cooling in the field for outof-hospital cardiac arrests? If not, patients resuscitated from out-of-hospital arrest will require HACA to be started in the emergency department. If the patient requires emergent cardiac catheterization, cooling can be started in the emergency department and continued in the procedural lab. Patients resuscitated from in-hospital arrest who remain comatose will require cooling in the intensive care unit. If patients are going to be cooled after in-hospital arrests, consider including this on the cardiac arrest documentation record as a reminder.
Determining How Long to Cool and at What Temperature
In the initial studies, Bernard et al (1) cooled patients to 33°C for 12 hrs, and the HACA trial (2) cooled patients to 32°C-34°C for 24 hrs. Both studies had similar survival and neurologic benefit. However, the absolute optimal temperature goal and the duration of therapy have not been specified. The International Liaison Committee on Resuscitation and the American Heart Association recommend the ranges listed here. Because of this limitation, your group will need to build consensus regarding the target temperature and duration of therapy.
Determining How Cooling Will Be Induced and Maintained
In the past few years cooling technology has evolved, providing many options for clinicians. This aspect of protocol development requires careful consideration from both a financial and a practical standpoint. The cooling method chosen must be one in which continuous temperature feedback and temperature control are integrated into the cooling system. This ensures safe temperature control and avoids overcooling. One method of cooling that should be avoided is the use of ice packs and water blankets, which have been associated with delayed time to target temperature and temperature overshoot (11) . Overcooling is dangerous and is associated with numerous complications such as dysrhythmias and coagulopathy. Acceptable and recommended cooling methods include surface cooling and the use of endovascular catheters.
Noninvasive surface cooling is an effective method of inducing and maintaining therapeutic hypothermia (12, 13) . Surface cooling is easy to use and can be initiated by nursing staff. Cooling pads are placed on the skin, covering as much body surface area as possible. Water circulates through the surface pads and is adjusted based on the patient's temperature. Circulating water temperature and skin condition under the surface pads should be documented at frequent intervals. Endovascular catheters are an effective method of inducing therapeutic hypothermia (14, 15) . The catheters are inserted into the inferior vena cava, usually through the femoral vein, and cool the blood as it passes the through catheter. Endovascular catheters are capable of cooling patients very quickly; however, the initiation of HACA can be delayed if a physician is not readily available for insertion. Careful consideration must be taken and the cooling method decision tailored to the resources available at your facility.
Two pilot studies evaluated the rapid administration of large-volume iced (4°C) saline in the field. Both studies infused iced saline for 20 -30 mins with an average decrease in temperature of 1.4°C within 30 mins (16, 17) . An additional study safely administered iced saline during the advanced life support effort (18) . Larger clinical trials are currently being conducted to evaluate the administration of iced saline in postresuscitation care.
EQUIPMENT AND MONITORING

Temperature Source
Regardless of whether endovascular catheters or surface cooling is used, a temperature source with continuous feedback to the cooling device is required to maintain the desired temperature range and avoid overcooling. There are two different methods of temperature monitoring: core and peripheral.
Core temperatures, which include pulmonary artery, esophageal, and tympanic readings, reflect temperature of the head and trunk and are considered more accurate than peripheral temperature sources. Esophageal temperature monitoring is the most practical method to continuously monitor core temperature. The esophageal temperature catheter is inserted orally, and the thermistor lies in the mid-esophagus. The position of the catheter can be verified by radiograph. The esophageal temperature sensor is connected to the cooling device to provide continuous temperature feedback. When compared with the "gold standard" pulmonary artery core temperature method, esophageal temperature readings are very accurate (pulmonary artery -esophageal temperature ϭ 0.11 Ϯ 0.30°C) and reliable (19) .
Peripheral temperature sources can also be used and reflect core temperature. Peripheral temperature sources include bladder, oral, axillary, and rectal sites. Bladder and rectal sources can be used for continuous temperature measurement; however, peripheral temperature may lag behind core temperature changes (20) . If a bladder source is selected, keep in mind that the temperature measurement may be dependent on adequate urine output.
Arterial Catheter
An arterial catheter may be necessary to closely monitor arterial blood pressure and to obtain frequent lab specimens. Placement of an arterial catheter should be considered in the induction phase of the protocol because cold-induced vasoconstriction may make arterial catheter placement more difficult.
Continuous Pulse Oximetry
Pulse oximetry is commonly monitored in the digits of critically ill patients. Because hypothermia causes peripheral cold-induced vasoconstriction, an alternate source should be used for accurate and reliable oximetry monitoring. Forehead sensors have shown to be accurate in the setting of hypothermia (21) . This alternate monitoring site can serve as a reliable method to monitor oxygen saturation because the forehead lacks sympathetic vasoconstrictive properties (22) . Many oximetry manufacturers offer fore- head sensors. Figure 1 illustrates an example of forehead oximetry monitoring.
Continuous Electroencephalogram
Many clinicians believe that it is essential to monitor intermittent or continuous electroencephalogram (EEG) to detect seizure activity, especially if using neuromuscular blocking agents to prevent or treat shivering (23) 
ORDER SETS AND PROTOCOL IMPLEMENTATION
Hypothermia has considerable benefits; however, it also has potential side effects as well. If healthcare providers do not understand physiologic changes caused by therapeutic hypothermia, many of the benefits can be negated. It is essential to integrate monitoring measures into the education plan as well as the protocol and order set.
Staff Education
A comprehensive staff education plan should be undertaken before implementation of the hypothermia protocol. Some key educational points include patient selection, physiologic effects of cooling, equipment used in the protocol (i.e., cooling device, temperature monitoring), the rewarming phase, and family education. Potential effects of hypothermia are outlined in the following paragraphs and summarized in Table 1 .
Nursing Considerations
Electrocardiographic Changes. Hypothermia causes electrocardiographic changes secondary to slowed impulse conduction through the myocardium, which is evidenced by prolonged PR, QRS, and QT intervals. In addition, cooling has a negative chronotropic effect on myocardial pacemaker cells; therefore, bradycardia is a common side effect of cooling. Anecdotally, bradycardia as low as 30 beats/min has been reported accompanied by stable mean arterial pressure and adequate urine output. The chronotropic effect can be quite alarming to staff caring for patients who are receiving therapeutic hypothermia. This teaching point must be stressed so patients are not needlessly given medications to accelerate the heart rate in the setting of hemodynamic stability.
Osborne or J waves are also commonly observed on the electrocardiogram. These waves are observed in association with hypothermia and are characterized as a positive deflection occurring between the QRS complex and ST segment. Clinical intervention for Osborne or J waves is not necessary, because this is a common electrocardiographic finding associated with hypothermia (24) .
Hemodynamics. Common hemodynamic changes observed with cooling include hypertension, decreased cardiac output, and increased systemic vascular resistance. Hypertension and systemic vascular resistance changes are caused by cold-induced vasoconstriction. Care must be taken to interpret all hemodynamic variables to avoid unnecessary therapy. For example, cardiac output may be reduced attributable to decreased metabolic demands. If a reduction in cardiac output is evidenced, observe the mean arterial pressure and urine output to assess the adequacy of perfusion.
Electrolyte imbalance. Cooling causes intracellular shifts of potassium, magnesium, calcium, and phosphate, resulting in abnormally low serum levels of these electrolytes. Conversely, during the rewarming phase, electrolytes shift back to the extracellular compartment. Serum chemistry levels must be monitored at regular intervals throughout the protocol; usually every 6 -8 hrs. Electrolytes should be replaced during the maintenance phase of the protocol, and replacement should be stopped during the rewarming phase.
Decreased CO 2 Production. As the patient's temperature decreases, CO 2 production slows. Many patients present with respiratory acidosis after initial resuscitation, and ventilator settings are tailored to correct the acidosis. However, the combination of high ventilator respiratory rates and slowed CO 2 production can cause profound alkalosis. Clinicians must be aware of these physiologic changes and assess arterial blood gases, adjusting ventilator settings accordingly. Oxygen administration also should be adjusted because there is a left shift on the oxyhemoglobin dissociation curve, which means that oxygen is not readily released to the tissue. Cooling also decreases the metabolic demand, which decreases oxygen consumption. The combination of the left shift and decreased metabolic demand can be manifested as elevated arterial oxygen concentration.
Coagulopathy
Publications from the 1950s frequently note coagulopathy as a common side effect with cooling therapy. However, coagulopathies were observed with temperatures Ͻ32°C. Coagulopathy is not as common with temperatures Ͼ32°C, although hypothermia is known to affect platelet function (25, 26) . Many HACA protocols include assessing baseline coagulation and platelet values. If active bleeding occurs during the protocol, ensure that coagulation and platelet values are corrected.
Hyperglycemia. Mild hypothermia physiologically suppresses insulin release and causes insulin resistance. Because hyperglycemia is a common side effect of hypothermia, blood glucose monitoring may be required at hourly intervals. Insulin protocols can be used to maintain glucose levels within a specificied goal (27, 28) . Hypothermia also causes peripheral vasoconstriction, especially in the fingers, a common site for obtaining capillary glucose measurement. Capillary glucose values can be falsely decreased in the setting of cold-induced vasoconstriction. An arterial catheter or central catheter may be a more reliable source for obtaining glucose and arterial blood gas measurement.
Infection. Mild hypothermia suppresses white blood cell production and impairs neutrophil and macrophage function. Precautions in preventing infection must be stressed in the protocol. Elevating the head of bed and preventing ventilator-associated pneumonia are critical elements of a hypothermia protocol and education plan. Baseline complete blood counts are usually assessed at admission and daily until the temperature has returned to normal. Daily chest radiography can also be helpful in identifying early pneumonia.
Special Nursing Considerations
Shivering. Shivering is a normal physiologic response to maintain thermal homeostasis. Prevention and treatment of shivering are among the most challenging aspects of therapeutic hypothermia. Shivering should be prevented because it slows the cooling process by generating heat, increases oxygen consumption up to 100%, increases metabolic demands, and increases intracranial pressure (29, 30) .
Multiple methods of preventing and treating shivering are discussed in detail in this supplement. However, there is not a proven "gold standard" shivering strategy that has been established in the therapeutic hypothermia population. Incorporate a clear shivering plan in the therapeutic hypothermia protocol and assess the plan as part of the postimplementation evaluation. Some protocols aim to prevent shivering and administer sedation and neuromuscular blocking agents upon cooling induction. Others treat clinical signs of shivering if it presents once cooling has been implemented. Clinical trials and ongoing investigations of best shivering management practice are warranted in the therapeutic hypothermia population.
If neuromuscular blockade is used in the protocol, note that peripheral nerve stimulation may not be a reliable method of monitoring blockade. Peripheral nerve conduction is slowed by cooling and is not a reliable monitoring method at temperatures in this treatment range (31) . Therefore, it may be necessary to evaluate for discontinuation of neuromuscular blockade at the end of each phase of cooling.
Prolonged Drug Clearance. Metabolism and clearance of many medications are prolonged in the presence of hypothermia. There is little research specifically studying medication clearance associated with hypothermia. However, there is evidence that hypothermia affects drug disposition in sedatives, neuromuscular blockade, anticonvulsants, and analgesics (32) . Special consideration must be taken when prescribing and administering medications during all phases of therapy. Possible actions include reducing medication doses and monitoring for drug toxicity.
Nursing Assessment. Nursing assessment during the protocol is unchanged with the exception of neurologic examination. The neurologic exam is generally limited to pupillary reactivity assessment because of medications administered to prevent shivering. This can be difficult for many bedside practitioners because it is engrained in critical care training to perform frequent neurologic assessment, especially in neurologically impaired patients. This may need to be a teaching point in the hypothermia education plan.
Controlled Rewarming
Controlled rewarming is the last phase of the protocol. Rewarming should be slow; typically at a rate of 0.25°C-0.5°C per hour. It is important for the nurse to monitor for hypotension because peripheral vascular beds vasodilate during the rewarming phase. Electrolyte levels should also be closely monitored because intracellular shifting of ions back into the serum occurs during the rewarming phase to maintain normothermia.
If a cooling device is used, it should be placed in an automatic mode and programmed to rewarm at a defined rate that is outlined in the hypothermia protocol. Rebound hyperthermia should be avoided once the goal temperature has been reached. This may be accomplished using the cooling device beyond the rewarming phase to maintain normothermia.
POSTIMPLEMENTATION
After the protocol has been developed, clinicians must continually evaluate the implementation and effect of this therapy. Because this is a relatively new treatment modality, it is important to perform surveillance of literature and maintain an evidence-based protocol. It may be necessary to revise the protocol after some experience is gained. A multidisciplinary therapeutic hypothermia group can be formalized with frequent meeting times to review patients who have received HACA; this may be done in conjunction with the committee that has oversight for cardiac arrest reviews. It is important to share successes and learning opportunities with staff caring for these patients.
SUMMARY
Numerous studies support the use of therapeutic hypothermia after cardiac arrest to decrease mortality rates and improve neurologic outcomes. However, the goals of resuscitation are not only to preserve cardiac and neurologic function but also to improve quality of life for survivors. HACA protocols need to be practical and cost-effective, using minimal resources while providing maximal benefit to cardiac arrest survivors.
A collaborative team approach is critical for the development and imple-mentation of a therapeutic hypothermia protocol. A formalized HACA protocol coupled with staff education is vital for success. A safe and effective protocol can support the critical care team and achieve the goals in the postresuscitation phase. Critical care nurses at many facilities have successfully championed this protocol.
When we implemented our first HACA protocol in 2002, many physicians and nurses were skeptical because traditionally, critically ill patients were rewarmed. The first patient we cooled had a prolonged "down time," received numerous defibrillations to terminate the lethal dysrhythmia, and remained comatose after resuscitation. Our cooling methods were challenging because we used ice packs and water blankets. Regardless, the patient was cooled for 24 hrs. Initially, the patient did not awaken when rewarmed to 37°C. However, 4 days later the patient was extubated and sitting on the side of the bed. I believe that this patient would have had a different outcome if he had experienced a cardiac arrest the year before. After almost 7 yrs of cooling, repeated stories like this have inspired nurses and physicians to continually evaluate the hypothermia protocol and review evidencebased practice to provide the optimal level of postresuscitation care.
